Profile

Glenmark Generics Inc. (GGI), USA is the North American division of Glenmark Generics Ltd. dedicated to the manufacture, marketing and distribution of generic pharmaceutical products. GGI (formerly Glenmark Pharmaceuticals Inc., USA) established operations in 2003 and was a subsidiary of Glenmark Pharmaceuticals Limited. In a short span of five years, the Company saw exponential growth in all areas and gained an impressive reputation in the industry as a driving force among its competition. Today, GGI is authorized to distribute 55 products which generates a finished dosage marketing portfolio yielding over 175 sku's (a mix of solid oral dosage and semi-solid preparations). GGI's products have high market penetration rates and double digit share almost across the board. Outstanding service levels can be attributed to the dedicated customer service teams put in place to ensure the smooth transition of products from the warehouse to customers.

Capabilities

GGI’s office is located in Mahwah, NJ, just 30 miles north of New York City and consists of both office space and a distribution center totaling over 75,000 square feet. Glenmark has built an impressive infrastructure and strengthened its integration across the pharmaceutical value chain through operations across its various manufacturing plants. In 2003, Glenmark purchased an API raw material plant from GlaxoSmithKline PLC, located in Ankleshwar, India and has received successful inspection by the FDA. In 2004, a state-of-the-art finished dosage manufacturing facility was completed in Goa, India. This highly automated plant has two separate manufacturing blocks, one for oral solid dosages and the other for semi-solid formulations. This plant serves as the main manufacturing facility for the United States market and was approved by the Food and Drug Administration in June 2005. Glenmark's focus on strategic planning and development has generated a robust pipeline in varying stages of maturity. Glenmark has over 45 abbreviated new drug applications (ANDA's) filed with the FDA pending approval. In addition to its internal filings, Glenmark has engaged in external development partnerships to supplement and accelerate the growth of its existing pipeline. Due to the strength and aptitude of its API team many of Glenmark's generic products enjoy the added benefit of vertical integration. This provides Glenmark with a competitive edge in the industry, realization of better margins and organic symmetry. Striving to enhance its capabilities and differentiate itself from the competition, Glenmark is consistently building upon its portfolio and marketing an assortment of dosage form products from various therapeutic categories. The Company is exploring and expanding its expertise into key arenas as hormones, oncology and other niche segments. Glenmark looks to utilize routes of administration such as extended release tablets and capsules, semi-solid preparations, solutions/suspensions, injectables and other platform technology products. Strong operational capabilities mixed with the opportunities available from possible new mergers and acquisitions provide the ability to achieve the Company's goals.